Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Gensia Pharmaceuticals Inc.


Analysts responded positively to GNSA's announcement that enrollment in its latest Phase III study of Protara was stopped by the San Diego company's independent panel after 2,500 patients had been analyzed (see BioCentury, Aug. 15).

Hambrecht & Quist analyst Alex Zisson upgraded the stock from

Read the full 492 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers